News & Updates

Visceral fat area (VFA) is a reliable prognostic indicator of muscle mass and is associated with nutritional, immune, and inflammatory status in patients with diverse types of cancer, such as gastric, colorectal, and nonsmall-cell lung cancers (NSCLC), claims a recent study.

People with idiopathic pulmonary fibrosis (IPF) who live near a major road tend to have a faster decrease in lung function, according to a study in Australia. Likewise, increased exposure to fine particulate matter (<2.5 μm, PM2.5) is associated with a higher rate of annual decline in diffusing capacity of the lungs for carbon monoxide (DLco).

In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).

For long-term users of combined oral contraceptives (COC), short-term hormonal withdrawal that occurs during the once-a-month pill pause appears to be accompanied by a significant increase in negative affect, anxiety, and mental health symptoms, regardless of COC type, as reported in a study.

Estimated glomerular filtration rate (eGFR) below age-expected values appears to indicate an increased risk for major adverse cardiovascular events (MACE) and MACE plus heart failure (MACE+) in young adults, according to a study.

Individuals with type 2 diabetes (T2D) who regularly consume ultraprocessed foods (UPF), regardless of diet quality, appear to have reduced survival and increased cardiovascular disease (CVD) mortality rate, suggests a recent study.

The Erection Hardness Scale (EHS) proves to be reliable in differentiating between predominantly organic and apparently nonorganic erectile dysfunction (ED), reducing the need for further nocturnal penile tumescence and rigidity (NPTR) testing, as reported in a study.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in significant weight loss in patients with obesity or overweight without diabetes, a study has shown. In addition, the best GLP-1RA agent appears to be semaglutide, showing superior efficacy and low-to-moderate risk of side effects.